Exenatide induces an increase in vasodilatory and a decrease in vasoconstrictive mediators

What Was Tested

The paper reports a study of Exenatide and ANP (Atrial Natriuretic Peptide), published as a randomized controlled trial.

In view of the known vasodilatory effects of glucagon-like peptide-1 and exenatide, the researchers investigated the effects of exenatide on vasoactive factors.

Who Took Part

The abstract describes 24 patients taking part.

How the Study Was Run

The researchers set it up as a randomized, single-blind and placebo-controlled study.

The patients were allocated by chance, so the Exenatide group and the comparison group should start out alike.

Only one side, usually the patients, was kept unaware of whether Exenatide was given.

The comparison arm used a placebo, so changes seen with Exenatide could be set against what happens without it.

The methods mention a period of 12 weeks.

What Was Measured

PubMed files the paper under topics including Adenylyl Cyclases, Angiotensinogen, Anti-Obesity Agents, Antihypertensive Agents, Atrial Natriuretic Factor, Blood Pressure and Cyclic AMP.

The authors tagged it with the keywords exenatide and vasodilatation.

What This Means in Plain Language

The paper is a randomized, single-blind and placebo-controlled study of Exenatide and ANP (Atrial Natriuretic Peptide) in 24 patients over 12 weeks.

With fewer than 40 people, it is a small study, so it is better read as an early signal for further research than as a settled answer.

The publication is from 2017 (Diabetes, obesity & metabolism), a journal based in England.

More context: the Exenatide compound page and the ANP (Atrial Natriuretic Peptide) compound page, all human trials.